The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results